Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases

Trial Profile

Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Immunodeficiency disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 11 Jan 2018 Baxalta merged with Shire in Jun 3, 2016.
    • 11 Jan 2018 Baxalta is the former Baxter BioScience global biopharmaceutical business spun off in July of 2015 by Baxter International with a focus on developing new treatments for people with orphan diseases and underserved conditions in three areas of therapeutic focus .
    • 16 Nov 2016 According to a Shire media release, based on the data from this and another phase III study (profile 278874), the U.S. Food and Drug Administration (FDA) has approved CUVITRU in September 2016 as a subcutaneous immune globulin (IG) replacement therapy for primary immunodeficiency.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top